Sumitomo Pharma Co., Ltd., is a global pharmaceutical company based in Japan with operations in the U.S. (Sumitomo Pharma America, Inc.), focused on addressing patient needs in oncology, urology, women's health, rare diseases, cell & gene therapies and CNS. Lead Phase 1 and special population clinical pharmacology studies (e.g., FIH, SAD, MAD, DDI, organ impairments, elderly/pediatric, PET/EEG), including protocol input, operational oversight, and interpretation and communication of results.